To meet an unmet medical need in bladder cancer diagnostics, VitaDX relies on innovative imaging in fluorescence and machine learning technologies. The startup is officially starting its second round of fundraising of 1.5 M€ due in the first quarter of 2017 to support the development of its non-invasive medical device.
Dear investors, if you wish to support us, and thus join our historic shareholders, we would be delighted to present you in more detail our overall strategy and managing team.
Please contact Allan Rodriguez, CEO: email@example.com – 06 98 46 24 68
The VitaDX team